FY2025 · ended Dec 31, 2025 · Revenue $727.33M, +10.1% YoY · Filed Feb 17, 2026
Neogenomics, Inc. (NEO) files with the SEC under industry code 8734, Services-Testing Laboratories. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $727.3 million and a net loss of $108.0 million. Free cash flow was -$21.8 million. As of Sep 30, 2026 it held $139.3 million in cash and investments and $449.1 million in total debt.
Revenue (TTM)
$787.75M
+11.1% vs year-ago TTM
Net income (TTM)
$-32.30M
+71.5% vs year-ago TTM
Operating cash flow (TTM)
$4.28M
-68.7% vs year-ago TTM
Free cash flow (TTM)
$-28.58M
-67.7% vs year-ago TTM
EPS (TTM)
$-0.25
+71.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
129.81M
+1.1% vs prior year
Net cash
$-309.86M
as of Sep 30, 2026
Operating margin
-6.3%
FY 2026
Company profile
- Industry
- Services-Testing Laboratories (SIC 8734)
- Listed as
- NEO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Fort Myers, FL
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1077183
- Former names
- AMERICAN COMMUNICATIONS ENTERPRISES INC (until Feb 5, 2002)
Other Services-Testing Laboratories companies
- UL Solutions Inc. ULS
- 20/20 Biolabs, Inc. AIDX
- Hypha Labs, Inc. FUNI
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $727.3M | $660.6M | $591.6M | $509.7M | $484.3M |
| Operating income | -$115.9M | -$92.1M | -$107.7M | -$157.6M | -$118.8M |
| Net income | -$108.0M | -$78.7M | -$88.0M | -$144.2M | -$8.3M |
| Operating cash flow | $5.2M | $7.0M | -$2.0M | -$66.0M | -$26.7M |
| Free cash flow | -$21.8M | -$34.0M | -$30.7M | -$96.9M | -$90.9M |
| Total assets | $1.4B | $1.6B | $1.7B | $1.7B | $1.9B |
| Total liabilities | $523.3M | $735.7M | $739.7M | $742.0M | $761.5M |
| Stockholders' equity | $836.6M | $902.3M | $941.5M | $998.0M | $1.1B |
| Cash and investments | $159.6M | $367.0M | $342.5M | $263.2M | $515.4M |
| Total debt | $409.5M | $605.3M | $611.7M | $610.9M | $612.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 28, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 28, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Results of operations, Officer or director change, Bylaw or fiscal year change
|
Oct 5, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 11, 2026 | Aug 7, 2026 |
| 10-Q | Quarterly report | Jul 28, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 28, 2026 | Jul 28, 2026 |
All 1001 Neogenomics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.